Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 14/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | CASP9 | P55211 | 2/20 | 0.40 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naphthalene SCHEMBL7422654 | 0.85 | CASP1 (0.42) | CASP1CAPN1CASP3CASP9CASP8 | |
| SCHEMBL7422646 | 0.82 | CASP1 (0.58) | CASP1HCRTR1HCRTR2 | |
| SCHEMBL7417591 | 0.80 | CASP1 (0.57) | CASP1CASP3CASP8HCRTR1HCRTR2 | |
| SCHEMBL7466002 | 0.75 | CASP1 (0.51) | CASP1CASP3CASP9CASP8LMNA | |
| SCHEMBL7463690 | 0.72 | CASP1 (0.45) | CASP1 | |
| SCHEMBL7418130 | 0.71 | CASP1 (0.72) | CASP1 | |
| SCHEMBL1273314 | 0.71 | CHRM2 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL7415539 | 0.71 | CASP1 (0.55) | CASP1CASP3CASP8 | |
| SCHEMBL7413795 | 0.67 | CASP1 (0.74) | CASP1 | |
| SCHEMBL7465656 | 0.67 | CASP1 (0.49) | CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0932598-A1 | ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 1999-08-04 | — | — | EP | claimed |
| CN-1211991-A | Compounds with growth hormone releasing properties | NOVO NORDISK AS (DK) | 1999-03-24 | — | — | CN | claimed |
| WO-1998016502-A1 | ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 1998-04-23 | — | — | WO | claimed |
| WO-2001019373-A2 | METHODS AND COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| CN-1269722-A | Method and composition for modulating responsiveness to corticosteroids | BASF AG (DE) | 2000-10-11 | — | — | CN | disclosed |
| EP-0998300-A1 | METHODS AND COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-10 | — | — | EP | disclosed |
| EP-0932598-A1 | ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 1999-08-04 | — | — | EP | disclosed |
| CN-1211991-A | Compounds with growth hormone releasing properties | NOVO NORDISK AS (DK) | 1999-03-24 | — | — | CN | disclosed |
| WO-1998041232-A2 | COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | disclosed |
| WO-1998016502-A1 | ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |